The U.S. Food and Drug Administration is adding its strongest warning to the label for Plavix after reports that some patients cannot process the blood thinning drug.
The FDA says certain patients with a genetic variation cannot metabolize the drug, putting them at increased risk for heart attack and stroke.
Patients can determine if they don't respond to Plavix by taking a …
Комментариев нет:
Отправить комментарий